Hypertension
Conditions
Interventions
Gold Standard:The laterality index (dominant aldosterone/cortisol ratio) in adrenal vein blood sampling is greater than 2, indicating unilateral dominant secretion.
Index test:1) The diagnostic value of peripheral blood 18 oxocortisol based on LC-MS/MS determination for unilateral dominant primary aldosteronism (PA)
2) The diagnostic value of standardized aldosterone ratios based on LC-MS/MS determination of steroids (17-a-hydroxyprogesterone, androstenedione, 18 oxycortisol, 18 hydroxycortisol, etc.) for unilate
Sponsors
Fuwai Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with primary aldosteronism; 2. Have the willingness to have adrenal gland surgery and the operation is feasible; 3. Sign the informed consent form for lateral adrenal vein blood collection; 4. Sign the written informed consent form for study enrollment.
Exclusion criteria
Exclusion criteria: 1) refusal to sign informed consent; 2) Patients diagnosed with other secondary hypertension (such as renal hypertension, renal artery stenosis, chromocytoma, Cushing's syndrome, etc., excluding sleep apnea syndrome); 3) eGFR <45 ml/min/1.73 m2, or patients with hepatic insufficiency (alanine aminotransferase and/or aspartate aminotransferase elevated more than 2.5 times the upper limit of normal); 4) Not stopping dihydropyridine calcium ion antagonists, B receptor blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists for at least 2 weeks, including aldosterone receptor antagonists (spironolactone, eplerenone), potassium-sparing diuretics (amiloride, triambenzine), potassium-excreting diuretics and licorice extract for at least 4 weeks; 5) Pregnant, trying to get pregnant, lactating women or patients who are currently taking sex hormones, glucocorticoids or are unable or unwilling to take safe contraceptive measures when undergoing examinations; 6) Patients at high risk of adrenal gland surgery who cannot tolerate surgery: 7) Patients without intention of adrenal surgery; 8) Conditions or medication regimens that are considered contraindications by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 18-oxocortisol; | — |
Secondary
| Measure | Time frame |
|---|---|
| Steroids (17-a-hydroxyprogesterone, androstenedione, 18 oxycortisol, 18 hydroxycortisol, etc.); | — |
Countries
China
Contacts
Public ContactMa Wenjun
Fuwai Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed